Ken Griffin Kodiak Sciences Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.2 - $3.25 $2,420 - $3,575	-1,100 Reduced 14.47%	6,500 $16,000
Q2 2024 Aug 14, 2024	SELL	$2.29 - $4.48 $66,639 - $130,368	-29,100 Reduced 79.29%	7,600 $17,000
Q1 2024 May 15, 2024	SELL	$3.01 - $7.45 $134,547 - $333,015	-44,700 Reduced 54.91%	36,700 $193,000
Q4 2023 Feb 14, 2024	BUY	$1.4 - $3.24 $2,940 - $6,804	2,100 Added 2.65%	81,400 $247,000
Q3 2023 Nov 14, 2023	SELL	$1.8 - $7.49 $222,300 - $925,015	-123,500 Reduced 60.9%	79,300 $142,000
Q2 2023 Aug 14, 2023	BUY	$4.3 - $9.48 $792,060 - $1.75 Million	184,200 Added 990.32%	202,800 $1.4 Million
Q1 2023 May 15, 2023	SELL	$4.81 - $8.88 $289,081 - $533,688	-60,100 Reduced 76.37%	18,600 $115,000
Q4 2022 Feb 14, 2023	SELL	$6.52 - $8.05 $82,152 - $101,430	-12,600 Reduced 13.8%	78,700 $563,000
Q3 2022 Nov 14, 2022	BUY	$7.57 - $12.5 $431,490 - $712,500	57,000 Added 166.18%	91,300 $707,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.